Paxman publishes newsletter on the world’s first biological evidence of how scalp cooling works to protect human hair follicles
Today, Paxman publishes the February issue of its newsletter aimed at shareholders, investors and other interested parties.
This issue highlights the recently published world’s first biological evidence of how scalp cooling works to protect human hair follicles from chemotherapy, based on research at Paxman Scalp Cooling Research Centre at the University of Huddersfield. This breakthrough research is a significant step forward for the understanding of how scalp cooling works, and it is already being used to further improve Paxman’s scalp cooling towards achieving the company’s ‘zero hair loss’ vision.
The newsletter also includes information on Paxman’s recently conducted directed share issue of 59 MSEK, planned installs at 20 locations in the USA in Q1 and Q2 in addition to upcoming installs already presented in the January issue of the newsletter, and that the company is recruiting to strengthen its presence in the key markets Europe and India.
To read the newsletter and subscribe for upcoming issues, follow this link:
http://bit.ly/paxfeb21en
PAXMAN’s investor newsletter is published monthly as a part of the company’s effort to strengthen its market communication together with the IR communication agency Honeybadger. Every published issue of the newsletter is available on PAXMANs website for investors, www.paxman.se. The company encourages feedback and requests on topics for upcoming issues of the newsletter.